Myelin oligodendrocyte glycoprotein antibody-associated disease is a rare condition where the immune system mistakenly attacks the protective covering around nerve fibers in the brain, spinal cord, and eyes, leading to vision problems, weakness, and confusion.

Understanding MOGAD: A Rare Neurological Condition

Myelin oligodendrocyte glycoprotein antibody-associated disease, commonly known as MOGAD, is a rare inflammatory disease that affects the central nervous system. The disease occurs when the body’s immune system, which normally protects us from illness, mistakenly identifies a healthy part of the nervous system as a threat and begins attacking it^[1]. This attack targets a protein called myelin oligodendrocyte glycoprotein, or MOG, which sits on the outer surface of myelin, the fatty protective covering that insulates nerve fibers in the brain, spinal cord, and optic nerves^[2].

The myelin sheath plays a crucial role in how our nervous system works. It acts like insulation around electrical wires, allowing nerve signals to travel quickly and efficiently from the brain to different parts of the body^[3]. When antibodies damage this protective layer in a process called demyelination, the messages that pass through these nerves become disrupted, slowed down, or blocked entirely. This disruption can affect vision, movement, sensation, and even cognitive function^[4].

MOGAD is considered a distinct disease entity, separate from other conditions that affect myelin. While it shares some overlapping features with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), MOGAD has unique characteristics in terms of its pathology, clinical presentation, and imaging features^[6]. Unlike MS, where chronic active lesions slowly expand over time, MOGAD typically presents with different patterns of inflammation and tissue damage^[6].

How Common Is MOGAD?

MOGAD is a relatively rare demyelinating disorder. Current estimates suggest it affects approximately 1 to 3 people per million each year^[2]. However, as awareness of this condition increases among healthcare professionals and more accurate testing methods become available, these numbers are expected to rise. The disease can affect people of any age, but research shows that the median age at onset is typically between 20 and 30 years^[6].

MOGAD affects men and women with similar frequency, showing no clear gender preference^[6]. There is also no clear racial or ethnic predominance identified in research studies^[6]. The condition can present at any point in life, though it is slightly more common in children and young adults compared to older age groups^[1]. Among pediatric cases, MOGAD has been found to occur more commonly in children than in adults, with males and females affected equally^[3].

What Causes MOGAD?

The exact cause of MOGAD remains unknown. Scientists understand that it is an autoimmune condition, meaning the immune system attacks the body’s own tissues rather than foreign invaders like viruses or bacteria^[5]. In MOGAD, the immune system forms antibodies specifically against myelin oligodendrocyte glycoprotein, a component of the myelin sheath that covers nerves in the brain and spinal cord^[3].

The specific location of MOG makes it particularly vulnerable to autoimmune attack. MOG is a protein found on the outer membrane of myelin sheaths, expressed primarily within the brain, spinal cord, and optic nerves^[4]. While its exact function is not fully understood, scientists believe MOG may act as a cell surface receptor or cell adhesion molecule, playing a role in myelin maturation, myelin integrity, and interactions between cells^[5].

MOGAD is not inherited and does not have a known genetic cause^[2]. However, the condition frequently develops after an illness, suggesting that infections may trigger the autoimmune response in susceptible individuals^[3]. The underlying pathophysiology of MOGAD is not fully understood, but researchers believe that MOG antibodies alone may not be directly pathogenic. Instead, they may contribute to disease through several mechanisms, including complement activation, opsonizing MOG (marking it for destruction), and antibody-dependent cellular cytotoxicity. T-cell activation and dysfunction of the blood-brain barrier are also believed to play important roles in MOGAD pathogenesis^[6].

Risk Factors for Developing MOGAD

While the precise reasons why some people develop MOGAD remain unclear, certain factors may increase the likelihood of developing this condition. Age appears to play a role, with children and young adults being slightly more likely to develop MOGAD compared to older adults^[1]. The condition can present at any age, but the median age of onset typically falls in the 20 to 30 year range^[6].

Recent infection or vaccination may also be associated with increased risk. MOGAD may develop after experiencing certain infections or receiving vaccinations, though this does not mean that vaccines cause the disease^[1]. The disease frequently occurs following a viral infection, suggesting that the immune system’s response to these infections may trigger the autoimmune attack on myelin in susceptible individuals^[3].

Recognizing the Symptoms of MOGAD

MOGAD causes painful inflammation in different parts of the central nervous system, leading to a variety of symptoms depending on which area is affected. The symptoms can appear suddenly and develop over the course of days, often becoming severe and debilitating^[1]. Understanding these symptoms is important because they can sometimes be confused with other neurological conditions.

One of the most common presentations of MOGAD involves inflammation of the optic nerve, a condition called optic neuritis^[1]. This is the most frequent symptom in adults and appears in many pediatric cases as well^[6]. People with optic neuritis may experience vision loss in one or both eyes, which can be severe. The vision loss is often accompanied by eye pain that worsens with eye movement^[1]. Other vision-related symptoms include blurry vision, double vision, and loss of color vision^[2]. In children, optic neuritis may sometimes be mistaken for a headache^[1]. Eye examinations often reveal disc edema, and in severe cases, peripapillary hemorrhages may be visible^[6].

Inflammation of the spinal cord, known as transverse myelitis, represents another major symptom pattern^[1]. When the spinal cord is affected, people may experience weakness or numbness in their arms or legs, muscle stiffness (called spasticity), or even paralysis. The specific symptoms depend on which part of the spinal cord is inflamed^[3]. Changes in sensation are common, including sharp, shooting pains or tingling sensations in the neck, back, or abdominal area^[2]. Problems with bowel, bladder, or sexual function may also occur due to disruption of nerve signals controlling these functions^[1].

When MOGAD affects the brain and spinal cord together, it causes a condition called acute disseminated encephalomyelitis, or ADEM. This is the most common presentation in children under ten years of age^[3]. Symptoms of ADEM include confusion, loss of balance and coordination, unsteady walking, behavioral changes, and loss of consciousness^[2]. People with ADEM may also experience vision loss and weakness^[1].

Additional symptoms that may occur with MOGAD include seizures, headaches, and fever^[1]. Some cases have been associated with cerebral cortical encephalitis, which can present with headaches, changes in mental function, and seizures^[3]. The brainstem or cerebellum may also be involved in some cases^[3].

How Symptoms Differ Between Adults and Children

MOGAD affects people differently depending on their age. In children, the disease most often targets the brain, causing ADEM with symptoms like confusion and loss of coordination. This frequently occurs alongside optic neuritis^[2]. Young children or those who present with ADEM are more likely to experience only one attack of the disease^[13].

In adults, MOGAD tends to target the spinal cord and eyes more prominently, leading to symptoms such as weakness, numbness, and blurry vision^[2]. Optic neuritis is more common in older children and adults^[3]. Adults with MOGAD are more likely to experience a relapsing course compared to children^[1].

The Course of MOGAD: Monophasic vs. Relapsing

MOGAD can follow different patterns over time, and understanding these patterns helps doctors plan appropriate treatment strategies. Some people experience only one attack of symptoms, which is called monophasic MOGAD. This single-episode pattern is slightly more common overall and accounts for about 40 to 50 percent of cases^[13][1].

Other people experience relapsing MOGAD, where symptoms go away for a period of time (called remission) before coming back (relapse)^[2]. In individuals who continue to test positive for MOG antibodies, the chance of relapse appears to be higher^[13]. Optic neuritis relapses occur in 30 to 50 percent of people with MOGAD, while ADEM associated with MOG antibodies sees relapses in about 38 percent of cases^[3].

Attacks usually develop over several days and can be severe and debilitating. Disability typically worsens with each attack, though recovery can take weeks to months^[1]. Interestingly, in individuals who experience relapses, later attacks tend to be less severe than earlier ones^[13]. The level of disability after MOGAD attacks is usually less severe than in NMOSD attacks, and recovery with treatment is typically better^[13].

Preventing MOGAD and Its Complications

Because the exact cause of MOGAD is unknown and the disease is not inherited, there are no specific measures known to prevent the initial development of the condition. However, for people who have already been diagnosed with MOGAD, particularly those with relapsing disease, preventive treatment with immunosuppressive medications may help reduce the likelihood of future attacks.

Early recognition and prompt treatment of attacks is important for preventing severe disability. Seeking medical attention immediately when symptoms appear can help ensure timely treatment that may improve outcomes. For individuals who have experienced severe initial attacks, some doctors may consider ongoing immunosuppressive treatment even after the first episode, though this approach does not have strong evidence supporting it^[13].

MOG antibodies may decrease over time and may not be detectable early in the disease or during remission, particularly in cases associated with ADEM^[13]. Regular monitoring and follow-up with healthcare providers can help track disease activity and adjust treatment plans as needed.

How MOGAD Changes Normal Body Function

To understand how MOGAD affects the body, it helps to know how the nervous system normally works. Nerve fibers throughout the brain, spinal cord, and optic nerves are covered with myelin, which acts like insulation around an electrical wire. This insulation allows electrical signals to travel quickly and efficiently along nerves, enabling rapid communication between the brain and the rest of the body.

In MOGAD, antibodies attack MOG, a protein on the outer surface of this myelin covering. The attack leads to inflammation and damage to the myelin sheath, disrupting the normal flow of nerve signals^[4]. The pathology of MOGAD is characterized by perivenous and confluent white matter demyelination^[6]. This means that areas of myelin loss cluster around small veins and can merge together to form larger affected regions.

MOGAD pathology differs from that of multiple sclerosis in several important ways. Unlike MS, MOGAD does not show the slowly expanding demyelinated plaques (chronic active lesions) that are characteristic of progressive MS^[6]. Instead, MOGAD lesions tend to have a different appearance and distribution. Cortical demyelination occurs in MOGAD and is more frequently intracortical rather than leukocortical, which is another distinguishing feature from MS^[6].

The inflammatory response in MOGAD also has distinct characteristics. Inflammatory infiltrates are mainly composed of CD4 T cells, whereas CD8 T cells predominate in MS^[6]. Granulocytic inflammatory infiltrates are also observed, and there is complement deposition within active white matter lesions^[6]. Importantly, selective loss of MOG protein in the lesions does not occur, and there is preserved expression of aquaporin-4 and absence of astrocytopathy, which helps differentiate MOGAD from aquaporin-4 positive NMOSD^[6].

When myelin is damaged, the messages traveling along affected nerves are slowed down, disrupted, or completely blocked. This explains why people with MOGAD experience problems with vision (when optic nerves are affected), movement and sensation (when the spinal cord is affected), or cognitive function and coordination (when the brain is affected). The specific symptoms that develop depend on which nerves and which areas of the central nervous system are damaged by the autoimmune attack.